The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis media (VT-AOM) and the safety of V114 with respect to the proportion of participants with serious adverse events (SAEs) through completion of the study. The primary hypothesis is that V114 is superior to no V114 in preventing VT-AOM as assessed by the incidence of VT-AOM.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with a First Episode of Vaccine-Type Acute Otitis Media (VT-AOM) Caused by the Pneumococcal Serotypes Contained in V114
Timeframe: Up to ~36 months
Percentage of Participants with Serious Adverse Events
Timeframe: Up to ~36 months
Percentage of Participants with Vaccine-Related Serious Adverse Events
Timeframe: Up to ~36 months
Percentage of Participants Who Discontinued the Study due to Serious Adverse Events
Timeframe: Up to ~36 months
Percentage of Participants Who Died
Timeframe: Up to ~36 months